DOTAP, (R)-
Recurrent Glioblastoma
University of FloridaSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
39 Active assets in the Recurrent Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 3 | BB |
Niraparib Ivy Brain Tumor Center | Phase 3 | BB |
FLUDEOXYGLUCOSE Jonsson Comprehensive Cancer Center | Phase 2 | B |
Atezolizumab Centre Hospitalier Universitaire Vaudois | Phase 2 | B |
Monomethyl Fumarate Alliance for Clinical Trials in Oncology | Phase 2/3 | B |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →